T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies.

88Background: Wartewig et al. (Nature 2017) proved in a preclinical mouse model that anti-PD1 therapy could cause T-cell lymphoma. T-cell lymphoma as an adverse event of CPIs has never been reporte...